Table 1:

Anticoagulation in older people with NVAF

• Efficacy of oral anticoagulation is maintained across all age groups even in the very old (≥85 years).

• Efficacy of oral anticoagulation is maintained across all CHADS2 scores even in those with low risk (CHADS2 score 1–2).

• The greatest net clinical benefit of oral anticoagulation is observed in those ≥85 years old due to their high base line stroke risk.

• Good quality of INR control is achievable regardless of age.

• Aspirin has very little benefit in stroke risk reduction in patients with NVAF and this benefit tends to be attenuated further in old age.

• Oral anticoagulation therapy remains superior to combination of antiplatelet agents.